Sector News

Sorin and Cyberonics Announce Appointment of LivaNova’s Chief Financial Officer

September 14, 2015
Life sciences

(BUSINESS WIRE) – Sorin S.p.A.,, a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc. a medical device company with core expertise in neuromodulation, today announced the appointment of Vivid Sehgal as Chief Financial Officer of LivaNova PLC (“LivaNova”) effective with the closing of the proposed merger of Sorin and Cyberonics. He will report directly to André-Michel Ballester, who will be the Chief Executive Officer of LivaNova, and will be based in the company’s London headquarters.

Mr. Sehgal brings more than 25 years of financial, operational and compliance leadership, most recently with Allergan, Inc., where he served as Senior Vice President, Treasury, Risk & Investor Relations, playing a lead role in the company’s capital deployment and risk strategies, culminating in the $66 billion sale of Allergan to Actavis plc.

Previously, Mr. Sehgal served as Vice President & Regional Controller of Allergan’s Europe, Middle East and Africa (EMEA) business, where he was responsible for finance, accounting, information technology, market research, data quality and sales operations covering more than 60 countries. He played a key role in the formulation and execution of the group’s strategy for international acquisitions and expansion into key emerging markets.

Prior to Allergan, Mr. Sehgal worked in various roles with GlaxoSmithKline and SmithKline Beecham for nine years, with his last position being Group Controller for the International Pharmaceutical Division, with sales of more than $13 billion. He brings additional financial leadership experience from other companies, including the Gillette Company during its acquisition by Procter & Gamble, Inc. and Grand Metropolitan plc.

“Vivid brings a wide variety of experience to LivaNova, including the development of shared services, strategic planning, Sarbanes-Oxley implementation and merger integration,” commented André-Michel Ballester, designated Chief Executive Officer of LivaNova and CEO of Sorin. “We are delighted to welcome Vivid as a key member of our senior management team.”

Greg Browne, Interim Chief Financial Officer of LivaNova, will continue to support LivaNova in a transitional capacity until, as previously announced, his retirement in mid-year of 2016.

Mr. Sehgal, who has lived and worked in the U.S., the U.K., Eastern and Central Europe, and the Middle East, earned a master’s degree in Finance and Investment from the University of Exeter and a bachelor’s degree in Economics from the University of Leicester. He is a member of the Chartered Institute of Management Accountants.

Source: Sorin

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach